Targeting Rab26 to Conquer Cisplatin-Resistant Lung Cancer with Self-Assembled DNA Nanomaterials

作者全名："Wang, Beinuo; Zhang, Ruijie; Wang, Yao; Qian, Hang; Wu, Di; He, Binfeng; Liao, Hu"

作者地址："[Wang, Beinuo; Liao, Hu] Sichuan Univ, West China Hosp Med, Dept Thorac Surg, Chengdu 610044, Peoples R China; [Wang, Beinuo; Qian, Hang; Wu, Di; He, Binfeng] Third Mil Med Univ, Xinqiao Hosp, Inst Resp Dis, Chongqing 400037, Peoples R China; [Zhang, Ruijie] Chongqing Med Univ, Dept Pulm & Crit Care Med, Hosp 2, Chongqing 400010, Peoples R China; [Wang, Yao] Gen Hosp Xinjiang Mil Command, Dept Resp Dis, Urumqi 830000, Peoples R China"

通信作者："Liao, H (通讯作者)，Sichuan Univ, West China Hosp Med, Dept Thorac Surg, Chengdu 610044, Peoples R China.; Wu, D; He, BF (通讯作者)，Third Mil Med Univ, Xinqiao Hosp, Inst Resp Dis, Chongqing 400037, Peoples R China."

来源：BIOMACROMOLECULES

ESI学科分类：BIOLOGY & BIOCHEMISTRY

WOS号：WOS:000967302000001

JCR分区：Q1

影响因子：5.5

年份：2023

卷号：　

期号：　

开始页：　

结束页：　

文献类型：Article; Early Access

关键词：　

摘要："Overcoming cisplatin-based drug resistance in lung cancer remains an enormous challenge in clinical tumor therapy worldwide. Recent studies have reported that some Rab GTPases are involved in multiple aspects of tumor progression, including invasion, migration, metabolism, autophagy, exosome secretion, and drug resistance. In particular, Rab26 is essential to vital processes such as vesicle-mediated secretion, cell growth, apoptosis, and autophagy. In this study, we developed a nanosystem based on programmed DNA self-assembly of Rab26 siRNA-loaded nanoparticles (siRNP). We demonstrated that siRNP could be effectively transfected into cisplatin-resistant A549 (A549/DDP) cells. These siRab26-carrying nanoparticles induced apoptosis and inhibited the disruption of autophagy. The combination therapy of siRab26 knockdown with cisplatin could improve the antitumor therapy compared with a single one in vitro. In nude mice, siRNP enhanced the chemosensitivity of cisplatin-resistant cells and inhibited tumor xenograft development. These outcomes suggest that siRNP is an effective platform for lung cancer therapy in cases exhibiting drug resistance."

基金机构："NSFC [81800086, 82070071]; Natural Science Foundation of Chongqing [cstc2019jcyj-msxmS0367, cstc2021ycjh-bgzxm0011]"

基金资助正文："This research was supported by an NSFC grant (81800086, 82070071)and the Natural Science Foundation of Chongqing (no.cstc2019jcyj-msxmS0367, cstc2021ycjh-bgzxm0011)."